Nasdaq puts $675 million Avalanche Treasury on the clock over two listing failures
Avalanche Treasury Corporation (AVAT) has until Feb. 2, 2027, to clear two Nasdaq listing deficiencies after its share…
Browsing Tag
USDC
2049 posts
If you use a Cypher or Osmosis card, your spending dies tonight and unbacked wallets could go with it
The Cypher wind-down, after payments company Nium acquired the crypto card and self-custody wallet provider, will end purchases…
Wintermute takes aim at Wall Street’s crypto ETF gatekeepers
Crypto trading giant Wintermute has secured a crucial foothold in US securities markets, clearing a major regulatory hurdle…
Coinbase is pulling Loopring trading today – finding a safe place to sell LRC tokens is getting complicated
Coinbase is scheduled to suspend LRC-USD trading on or around 2 p.m. ET on Aug. 7. If completed,…
Inside the uncollateralized deal that locked up 6 million SUI until 2028 while SUI Group trades at a 25% NAV discount
SUI Group Holdings has lent 6 million SUI tokens to Bluefin Markets under an uncollateralized agreement that lets…
Circle shrugs off stablecoin profit fall, preps launch of Arc mainnet
Circle’s Q2 report reveals rising revenue but declining profits amid shifting interest rates and strong competition in the…
USDC redemptions just outpaced mints by $4B, but a massive new token presale is quietly doubling Circle’s revenue outlook
Circle’s reserve engine absorbed a tough second quarter. Gross USDC redemptions exceeded mints by about $4 billion, and…
After 3 reverse stock splits and a $13.5M loss, this real estate firm bet $8M on crypto it may not be allowed to withdraw
Real estate services company La Rosa Holdings put $8.14 million of digital assets on its March 31 balance…
Coinbase posts third straight quarterly loss as retail traders give up
Coinbase extends its losing streak with another quarterly loss as weaker trading activity and changing user behavior weigh…
Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug
Enlivex, a Nasdaq-listed biotechnology company, is asking shareholders to authorize up to $800 million of financing tied to…